BofA raised the firm’s price target on Pharvaris (PHVS) to $13 from $11 and keeps an Underperform rating on the shares after the company announced the FDA has lifted the clinical hold on the IND evaluating deucrictibant as an oral prophylaxis hereditary angioedema, or HAE, treatment. The firm highlights the HAE space as “one of the more crowded rare disease markets” with clinical competitor Ionis Pharmaceuticals (IONS) just announcing their phase 3 prophylaxis program met its primary endpoint of reduction in rate of HAE attacks and adds that it continues to assume that most patients will go for the most efficacious drug, regardless of how it is dosed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHVS:
- Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Pharvaris announces FDA lifting of clinical hold of deucrictibant in HAE attacks
- Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
- Pharvaris provides business update
- Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023